Company Monitoring Page for Novartis

latest headlines for company on cafepharma

Novartis investors demand action amid 'swamp' of bribery allegations in Greece
Fierce Pharma
Mon, 03/5/18 - 02:49 pm
Tags:
Novartis, investors, bribery, Greece
Novartis wants to be a leader in a new generation of prescription digital med programs, pairs with Pear
Endpoints
Thu, 03/1/18 - 11:10 am
Tags:
Novartis, Pear Therapeutics, prescription digital medicine
Sucking up talent out of Novartis, a booming Rubius adds another $100 million mega-round to the kitty
Endpoints
Thu, 03/1/18 - 09:49 am
Tags:
Novartis, Rubius
Novartis rolls out heart-helping data for Ultibro COPD edge
Fierce Pharma
Sun, 02/25/18 - 11:25 am
Tags:
Novartis, COPD, Ultibro Breezhaler
Greek lawmakers launch probe into 10 officials accused of taking Novartis bribes
Fierce Pharma
Thu, 02/22/18 - 11:15 pm
Tags:
Greece, Novartis, bribery
Novartis Expects FDA and EMA Approvals for Aimovig in 2018
Yahoo/Market Realist
Wed, 02/21/18 - 09:47 am
Tags:
Novartis, FDA, EMA, drug approvals, Aimovig, migraines
ICER declares costs of approved CAR-T therapies aligned with clinical benefit
BioWorld
Tue, 02/20/18 - 09:58 am
Tags:
CAR-T, ICER, Gilead Sciences, Yescarta, Novartis, Kymriah, drug pricing
Novartis’ Kymriah: The First Gene Therapy to Be Approved in the US
Market Realist
Mon, 02/19/18 - 09:48 am
Tags:
Novartis, Kymriah, gene therapy, acute lymphoblastic leukemia
Novartis May Sell U.S. Generic Pill Business Amid Industry Struggles
TheStreet.com
Sat, 02/17/18 - 10:53 am
Tags:
Novartis, generics, M&A
Novartis beefs up its data bank on Cosentyx’s durable effect on quality of life as well as scalp psoriasis
Endpoints
Fri, 02/16/18 - 09:32 pm
Tags:
Novartis, Cosentyx, psoriasis
Eli Lilly touts PhIII success for Taltz as rival Novartis stays well out front in crowded immunology race
Endpoints
Tue, 02/13/18 - 09:45 am
Tags:
Eli Lilly, Taltz, Novartis, ankylosing spondylitis, Cosentyx
Novartis, Momenta grab a delayed FDA OK for blockbuster Copaxone knockoff
Endpoints
Tue, 02/13/18 - 09:11 am
Tags:
Novartis, Momenta Pharmaceuticals, FDA, Copaxone, Teva Pharmaceutical, Glatopa, MS, multiple sclerosis
Roche posts positive PhII results for bispecific antibody eye drug, joining Novartis in rivalry with Eylea
Endpoints
Mon, 02/12/18 - 09:49 am
Tags:
Roche, bispecific antibodies, RG7716, Novartis, Eylea
Novartis could cut its Kymriah price to $160,000 and keep its profit margins: study
Fierce Pharma
Thu, 02/8/18 - 11:55 pm
Tags:
Novartis, Kymriah, pricing
Patient Advocate Says Novartis' $475,000 Breakthrough Should Cost Just $160,000
Forbes
Thu, 02/8/18 - 11:47 pm
Tags:
Novartis, drug pricing, Kymriah
No more Mr Nice Guy: GlaxoSmithKline is coming out of its corner swinging
Endpoints
Thu, 02/8/18 - 11:18 am
Tags:
GSK, R&D, Pharma CEOs, Emma Walmsley, Advair, Novartis, Sandoz, Gilead Sciences, HIV
FDA rejects Novartis’ Advair generic, leaving GSK without rival
Drug Delivery Business News
Thu, 02/8/18 - 09:17 am
Tags:
FDA, Novartis, Advair, generics, GSK, Sandoz
Pfizer's manufacturing fix clears path for Momenta's Copaxone generic
Biopharma Dive
Thu, 02/1/18 - 09:45 pm
Tags:
Pfizer, drug manufacturing, generics, Momenta Pharmaceuticals, Copaxone, Novartis
Joe Jiménez, Novartis outgoing CEO, describes group’s strategy
GoinPharma
Thu, 02/1/18 - 09:27 am
Tags:
Joe Jimenez, Novartis, Pharma CEOs
Cancer drug to treat dwarfism? Abandoned Novartis asset snagged by BridgeBio’s QED Therapeutics
Endpoints
Wed, 01/31/18 - 09:20 am
Tags:
Novartis, dwarfism, infigratinib, BridgeBio

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.